Beckman Coulter receives FDA clearance for bacterial infection test
Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.
How this was made
The 30-second read
Why it matters
The clearance adds a rapid bacterial infection test, potentially reducing antibiotic use and hospital costs.
Market read
First FDA clearance for this assay; may boost Danaher’s diagnostics segment and influence sector sentiment.
What to watch
Reimbursement rates and hospital procurement cycles could delay revenue realization.
Background
Danaher’s Beckman Coulter Diagnostics develops immunoassay platforms; FDA clearances are key growth drivers.
Ticker impact
FDA clearance of Beckman Coulter's Access MeMed BV assay expands Danaher's diagnostic portfolio.
potential upside as investors price in expanded test offering
Regulatory approval is a material catalyst for a large, diversified medical device company.
Market effects
strengthens the broader diagnostics and infectious disease testing sector.
U.S. market may see increased demand for rapid bacterial/viral differentiation tests.
could influence global competitors to accelerate similar FDA submissions.
Counterpoint
If adoption is slower than expected, the clearance may have limited near-term impact.
Key entities
- CompanyDanaher Corporation
Parent company of Beckman Coulter Diagnostics.
- CompanyMeMed
Partner developing the host-response diagnostic assay.
